HIV-associated lymphoma: promising new results, but with toxicity

Blood. 2005 Mar 1;105(5):1842. doi: 10.1182/blood-2004-12-4729.

Abstract

Treatment of HIV-associated non-Hodgkin lymphoma with rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide resulted in high complete remission and 2-year failure free and overall survival rates but a high rate of infection.

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / toxicity
  • Cyclophosphamide / therapeutic use
  • Disease-Free Survival
  • Doxorubicin / therapeutic use
  • Drug-Related Side Effects and Adverse Reactions
  • Etoposide / therapeutic use
  • Humans
  • Infections / chemically induced
  • Lymphoma, AIDS-Related / complications
  • Lymphoma, AIDS-Related / drug therapy*
  • Lymphoma, AIDS-Related / mortality
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide